Skip to main content
DYAI
NASDAQ Life Sciences

Shareholders Authorize Board to Implement Reverse Stock Split to Address Nasdaq Delisting Threat

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.798
Mkt Cap
$28.495M
52W Low
$0.655
52W High
$1.346
52W Position info
22% above low
Off High info
41% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

DYAI sits 22% above its 52-week low of $0.655.

Summary

Dyadic International shareholders approved the board's authorization for a reverse stock split, a crucial move to address the company's ongoing Nasdaq delisting issues.


Key Events · Corporate Governance and Compliance · DYAI

  • Reverse Stock Split Authorized

    Shareholders approved the board of directors' authorization to effect a reverse stock split of the company's common stock, by a ratio in the range set forth in the Proxy Statement.

  • Addresses Delisting Threat

    This authorization is a direct response to Nasdaq's recent initiation of delisting proceedings against Dyadic International for failing to meet the minimum bid price requirement.

  • Routine Proposals Passed

    Shareholders also approved the election of a Class I director, ratified the appointment of Crowe LLP as the independent auditor, and passed an advisory vote on executive compensation.


Analysis · DYAI · Life Sciences

Shareholders of Dyadic International have approved the board's authority to execute a reverse stock split. This is a critical step for the company as it faces imminent delisting from Nasdaq due to its failure to meet the minimum bid price requirement. The authorization provides the company with a necessary tool to potentially regain compliance and maintain its public listing, which is vital for its access to capital and investor visibility.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYAI was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.5M. The 52-week trading range was $0.65 to $1.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYAI - Latest Insights

DYAI
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.327
Real-time Price: $0.330 info
Change: +$0.0030 (+0.92%) info
Market Cap: $13.234M info
DYAI
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3501
Real-time Price: $0.330 info
Change: -$0.0201 (-6%) info
Market Cap: $13.234M info
DYAI
Sep 25, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4198
Real-time Price: $0.330 info
Change: -$0.0898 (-21%) info
Market Cap: $13.234M info
DYAI
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.330 info
Change: -$0.380 (-54%) info
Market Cap: $13.234M info
DYAI
Aug 14, 2026, 9:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7702
Real-time Price: $0.330 info
Change: -$0.4402 (-57%) info
Market Cap: $13.234M info